We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




New Version of Old Drug Shows Promise for Treating Drug-Resistant Tuberculosis

By LabMedica International staff writers
Posted on 15 Jun 2015
Print article
Image: DNA polymerase forms a homodimeric ring (shown as blue cartoon and surface representation). Each polypeptide chain binds one molecule of griselimycin (red). The optimized compound cyclohexylgriselimycin contains an additional cyclohexane moiety (yellow, shown only for the ligand in the foreground) (Photo courtesy of the Helmholtz Centre for Infection Research).
Image: DNA polymerase forms a homodimeric ring (shown as blue cartoon and surface representation). Each polypeptide chain binds one molecule of griselimycin (red). The optimized compound cyclohexylgriselimycin contains an additional cyclohexane moiety (yellow, shown only for the ligand in the foreground) (Photo courtesy of the Helmholtz Centre for Infection Research).
A team of molecular microbiologists has determined the mechanism by which the Streptomyces-derived antibiotic griselimycin blocks the growth of Mycobacterium tuberculosis, the bacterium responsible for causing more than eight million cases of tuberculosis annually on a worldwide basis.

Investigators from the Helmholtz Center for Infection Research (Braunschweig, Germany), other German research institutes, and the biomedical company Sanofi (Paris, France) were interested in exploring the possibility of using griselimycin or one of its derivatives for treating drug resistant tuberculosis; while this drug had been evaluated in the 1960's it had suffered in comparison to others. However, M. tuberculosis has developed resistance to most of those other drugs, and development of replacements is a top priority.

The investigators reported in the June 5, 2015, issue of the journal Science that a variant of griselimycinm, cyclohexylgriselimycin, was particularly effective against M. tuberculosis, in cells and when administered orally to an animal model.

The effectiveness of cyclohexylgriselimycin was found to be due to the drug's inhibition of the M. tuberculosis DNA polymerase sliding clamp DnaN. A DNA clamp, also known as a sliding clamp, is a protein fold that serves as a processivity-promoting factor in DNA replication. Processivity is an enzyme's ability to catalyze consecutive reactions without releasing its substrate. As a critical component of the DNA polymerase III holoenzyme, the clamp protein binds DNA polymerase and prevents this enzyme from dissociating from the template DNA strand. The clamp-polymerase protein–protein interactions are stronger and more specific than the direct interactions between the polymerase and the template DNA strand; because one of the rate-limiting steps in the DNA synthesis reaction is the association of the polymerase with the DNA template, the presence of the sliding clamp dramatically increases the number of nucleotides that the polymerase can add to the growing strand per association event. The presence of the DNA clamp can increase the rate of DNA synthesis up to 1,000-fold compared with a nonprocessive polymerase.

As inhibiting the DNA clamp is a completely different mechanisms from those of antibiotics now used against tuberculosis and other bacterial pathogens, the investigators consider that the risk of developing resistance to cyclohexylgriselimycin is low.

"We hope that cyclohexylgriselimycin will become an agent that can even be used against resistant tuberculosis pathogens in the future and contributes to a more successful fight against this dreadful disease," said senior author Dr. Rolf Müller, head of the department of microbial natural products at the Helmholtz Centre for Infection Research. "In the tuberculosis pathogen, the substance binds to the so-called DNA clamp and thus suppresses the activity of the DNA polymerase enzyme, which multiplies the genetic information inside the cell. We resumed the work on this agent and optimized it such that it shows excellent activity in the infection model—even against multi-resistant tuberculosis pathogens."

Related Links:

Helmholtz Centre for Infection Research
Sanofi


Gold Member
Turnkey Packaging Solution
HLX
Antipsychotic TDM AssaysSaladax Antipsychotic Assays
New
Anti-Secukinumab ELISA
LISA-TRACKER anti-Secukinumab
New
Automatic Biochemistry Analyzer
Audmax 180 Evolution

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The smartphone technology measures blood hemoglobin levels from a digital photo of the inner eyelid (Photo courtesy of Purdue University)

First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC

Blood hemoglobin tests are among the most frequently conducted blood tests, as hemoglobin levels can provide vital insights into various health conditions. However, traditional tests are often underutilized... Read more

Immunology

view channel
Image: Under a microscope, DNA repair is visible as bright green spots (“foci”) in the blue-stained cell DNA. Orange highlights actively growing cancer cells (Photo courtesy of WEHI)

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Every year, hundreds of thousands of women across the world are diagnosed with ovarian and breast cancer. PARP inhibitors (PARPi) therapy has been a major advancement in treating these cancers, particularly... Read more

Microbiology

view channel
Image: HNL Dimer can be a novel and potentially useful clinical tool in antibiotic stewardship in sepsis (Photo courtesy of Shutterstock)

Unique Blood Biomarker Shown to Effectively Monitor Sepsis Treatment

Sepsis remains a growing problem across the world, linked to high rates of mortality and morbidity. Timely and accurate diagnosis, along with effective supportive therapy, is essential in reducing sepsis-related... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.